Skip to main content

Table 2 Overall VFQ-25 subscale scores (all indications) as well as stratified data of treatment-naïve and pre-treated patients

From: Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study

 

Baseline score [95 % confidence interval]

VFQ-25 subscale

All (N = 4844)a

Naïve (N = 3414)a

Pre-treated (N = 741)a

General health

45.3 [44.7; 45.8]

45.9 [45.3; 46.6]

43.8 [42.4; 45.3]

General vision

59.5 [59.0; 60.0]

59.7 [59.1; 60.3]

58.8 [57.4; 60.1]

Ocular pain

86.5 [85.9; 87.0]

87.2 [86.6; 87.8]

85.8 [84.4; 87.1]

Near vision

67.0 [66.2; 67.7]

67.8 [67.0; 68.7]

64.1 [62.2; 66.1]

Distance vision

70.7 [69.9; 71.4]

71.9 [71.0; 72.7]

66.2 [64.2; 68.3]

Social function (vision specific)

83.8 [83.1; 84.5]

84.9 [84.1; 85.7]

81.4 [79.5; 83.2]

Mental health (vision specific)

67.9 [67.3; 68.6]

68.8 [68.0; 69.5]

65.1 [63.3; 67.0]

Role limitations (vision specific)

69.2 [68.4; 70.1]

70.5 [69.4; 71.5]

64.6 [62.2; 67.0]

Dependency (vision specific)

82.1 [81.3; 82.9]

83.3 [82.4; 84.2]

79.8 [77.6; 81.9]

Driving

59.6 [58.3; 60.9]

60.0 [58.5; 61.6]

54.1 [50.5; 57.6]

Colour vision

89.6 [89.0; 90.2]

90.3 [89.6; 91.0]

89.1 [87.5; 90.6]

Peripheral vision

74.9 [74.1; 75.6]

76.2 [75.3; 77.1]

71.2 [69.2; 73.2]

  1. aMissing data for <3 % in subscale scores; except for driving, which is only reported for those subjects who reported to currently drive or to have given up driving mainly due to eyesight